Nasdaq slips as chip and AI-linked stocks weaken; Eli Lilly shares buck the trend

U.S. stocks traded lower on Tuesday, with the Nasdaq composite pacing declines, while some individual large-cap names managed to hold up better than the broader market. Market coverage highlighted Eli Lilly as a standout, even as other sectors, particularly semiconductors and AI-adjacent stocks, came under pressure.

The day’s broad pattern was reflected in reporting that pointed to renewed caution around AI expectations and the chip complex. Investor’s Business Daily said chip and other AI names sold off after Samsung Electronics earnings, which it described as beating views but not convincing the market enough to drive a rally in AI-linked names.

Within the technology tape, memory and semiconductor-related stocks drew specific attention. The Yahoo Finance market wrap singled out Sandisk and Micron as among the companies falling, placing pressure on the closely watched memory supply chain and businesses tied to data storage demand.

Also in the semiconductor group, Micron’s move was flagged in the broader context of market back-and-forth around valuation and demand indicates. That theme is consistent with the way markets often react to major memory industry updates, where even “better than expected” results can still leave investors focused on longer-term pricing and utilization trends.

Despite the negative tone in much of semiconductors, Eli Lilly was highlighted as gaining, suggesting investors may have rotated toward healthcare risk profiles or company-specific momentum while technology indexes struggled. The Yahoo Finance wrap described Eli Lilly as “shining” in contrast to the day’s market losers.

Beyond semiconductors, other components of the major averages had mixed performances. Yahoo’s daily market overview also referenced IBM as a big winner in the Dow Jones, underscoring that the day’s weakness was not uniform across indexes and that leadership was split between defensive and cyclical exposures.

For investors and business watchers, the key takeaway is less about a single company headline and more about market dispersion, where index-level weakness can coexist with firm-specific strength. In this session, that dispersion showed up both in the relative resilience of certain healthcare names and the sharper drawdown in parts of the chip stack tied to AI and memory.

It remains unclear from the market wrap alone what exact catalyst drove Eli Lilly’s outperformance that day. The Yahoo Finance post focused on relative performance categories rather than attributing the move to a specific trial update, regulatory decision, guidance change, or analyst action, and the additional web context did not provide Eli Lilly-specific operational details.